Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from OPDC Career Development Fellow Natalie Connor-Robson investigates how mutations in the gene LRRK2, which are known to cause Parkinson’s, affect normal cell function.

Most cases of Parkinson's are idiopathic, which simply means that we don't know the causeWhile only a small portion of all cases are thought to be directly linked to a genetic cause, researchers believe that understanding the genetic factors may lead to a greater understanding of how Parkinson's develops and provide key information on potential approaches to treatment.

Mutations in the LRRK2 gene are considered to be the most common factor in the development of Parkinson's. Dr Natalie Connor-Robson from the Wade-Martins Group has found compelling new evidence for exactly how mutations in the LRRK2 gene disturbs normal cell function.

Read the full article on the OPDC website.

Similar stories

Researcher publishes children's book of the brain

Postdoctoral Publication

Betina Ip, a Royal Society Dorothy Hodgkin Research Fellow based in NDCN, formerly a postdoctoral research scientist in DPAG, has written a book for children: The Usborne Book of the Brain and How it Works.

New laboratory space for OPDC Researchers

OPDC News

A major building in the centre of Oxford has been constructed to create a new research centre bringing together cellular neuroscience and physical sciences.

Dopamine neurons need a 'REST' in Parkinson’s Disease

OPDC News

A study led by University of Oxford researchers, Dr Brent Ryan and Dr Nora Bengoa-Vergniory has shown that the key protein RE1 Silencing Transcription Factor (REST) regulates the health of those neurons critically affected in Parkinson’s Disease.

Drug trial that could improve respiratory recovery from COVID-19 now underway

Research

A clinical trial has commenced this week to test whether a drug called almitrine can help people who are seriously ill with COVID-19 to recover from the disease.

Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer's disease

OPDC News

A study led by the Oxford Parkinson’s Disease Centre’s (OPDC) Dr Nora Bengoa-Vergniory has shown that a novel assay termed the tau-proximity ligation assay is able to recognise Alzheimer’s disease before current detection methods.